When tirzepatide's UK list price rose by up to 170 percent in September 2025, the number of self-paying patients starting semaglutide instead jumped 31 percentage points above where the earlier trend said it should be. No new trial changed. No label changed. The price changed, and roughly a million people's prescribing choices moved with it.
That is the finding of a retrospective study of 1,033,522 UK adults ↗ published online October 14 in Diabetes, Obesity and Metabolism. The authors, from the telehealth company HeliosX and the consultancy Lane Clark & Peacock, tracked every adult who started semaglutide (sold as Wegovy and Ozempic) or tirzepatide (Mounjaro and Zepbound) through the online pharmacy MedExpress between May 2024 and January 2026. Most of that window, tirzepatide dominated: 932,659 people, or 90 percent of starts, versus 100,863 for semaglutide.
Then Eli Lilly raised tirzepatide's UK list price. The researchers used a segmented interrupted time-series, a method that projects the pre-change trend forward and measures how far reality departs from it. Semaglutide initiation rose 31.15 percentage points above the projection (95 percent confidence interval 26.07 to 36.24). Switching from tirzepatide to semaglutide rose 9.26 points (95 percent CI 7.09 to 11.42) before easing back. The move started early: the authors found anticipatory shifts in August, a month before the increase landed, which is what you would expect from a market where patients read the news and pay the bill themselves.
That self-pay structure is the reason this study exists at the size it does. In the self-funded market, price is not an abstraction absorbed by an insurer or a health system. It is the patient's problem, and the patient can switch molecules with a few clicks. A natural experiment on the price elasticity of a prescription drug at million-person scale is rare, and this one points the obvious direction: demand for these drugs is sensitive to relative price, not just to how well they work.
How well they work is where the study earns its asterisk. The authors also reported estimated 12-month weight loss of 19.93 percent for tirzepatide and 16.40 percent for semaglutide. Read quickly, that looks like a head-to-head win for tirzepatide. It is not. The tirzepatide estimate rests on 30,763 people; the semaglutide one rests on 979. A thirtyfold gap in denominator, in a retrospective single-provider cohort where patients chose their own drug, is not a trial. It is a snapshot of who stayed on what, shaped by who could afford to.
Two more caveats sit on the data. The study covers one telehealth provider, so "the UK market" here means MedExpress customers, not the NHS or every private clinic. And the paper was written by that provider together with a consultancy, which is commercial authorship reporting on its own order book. The switching signal is large and the method is sound, but the frame is a company describing its own customers.
For the molecular picture underneath the price war: tirzepatide ↗ hits two incretin receptors, GLP-1R ↗ and GIPR ↗, while semaglutide ↗ hits GLP-1R alone. In the trials, the dual agonist loses more weight. In the September 2025 UK market, the single agonist got cheaper, and cheaper won a large share of the new starts. We covered the other side of that math last month, when a Lilly-authored cost analysis ↗ argued tirzepatide still cost less per patient who hit target. Both things can be true. Patients paying out of pocket in real time answered the pricing question their own way.